Melhores podcasts sobre Theranostics (2024)

1
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics 40:45

27d ago40:45

40:45

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics. Read the Commission: https:/…

1
Bringing PRRT to First Line: NETTER-2 28:48

3d ago28:48

28:48

Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implication…

1
Reducing the ALS Diagnostic Delay: The Impacts of a Rapid Access Clinic

5d ago

—

Guest: Kelly Gwathmey, MD ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an average of two months sooner. Here to talk about this work is Dr. Kelly Gwathmey, Professor of Neurology at…

1
NUKED: Our nuclear future, with Novartis, Wilsons Advisory and Cyclotek 34:16

19d ago34:16

34:16

Drone-deliveries of radioactive medicines and diagnostics to Australia's far-flung towns. Radiopharmaceuticals matched with genetic information to tailor precisely the right dose and isotope to a person's cancer. Pan-cancer drugs that fix many tumours, not just one. Miniature particle accelerators. These are the hopes, dreams and expectations we ca…

1
NUKED: Patent puzzles, with FB Rice 25:20

26d ago25:20

25:20

The rule of thumb in biotech is that it costs around $1 billion to bring a new therapy from lab to market. Protecting that investment is the patent system. But what if part of your product is not made by your contract manufacturer, but by the people who are giving it to patients? Ie, their doctors. We explore an example in Australia where this push…

1
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination 17:21

27d ago17:21

17:21

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Read the full Article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanon…

1
How CRC Screenings Could Help Reduce Colonoscopy Backlog: A DDW Poster

27d ago

—

Host: Jennifer Caudle, DO Guest: A. Mark Fendrick, MD Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn …

1
NUKED: Australia the nuclear power, with entX and Cyclowest 29:58

1M ago29:58

29:58

Can Australia create a mine to lab to bedside production line for radiopharmaceutical medicine? It has the reactor, biotechs and the hospitals to do that last two, and even has a growing pool of expertise to run these. What it doesn't have, yet, is many advanced manufacturers to do the first bits, the critical parts such as sifting through old mine…

1
NUKED: The IP game, with Clarity Pharmaceuticals and Radiopharm Theranostics 26:25

1M ago26:25

26:25

The question we are dancing around in episode 3 of NUKED is whether locking down isotopes supply chains are really the only way to play the radiopharmaceutical game. We ask Clarity Pharmaceutical executive chair Alan Taylor and Radiopharm Theranostics executive chair Paul Hopper how their companies are instead owning the IP, or banking a portfolio …

1
NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals 29:47

2M ago29:47

29:47

In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules. In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical tri…

1
NUKED: Why radiopharmaceuticals are exploding, with Peter MacCallum Cancer Centre and HB Biotechnology 25:34

2M ago25:34

25:34

The radiopharmaceuticals sector is on a knife point. The scope of what nuclear medicine can do is exploding. But the radioisotopes that biotechs need to make those therapies are in very, very short supply. Major clinical trials are hitting pause because of shortages of critical nuclear isotopes, and the world's biggest pharmaceutical companies are …

1
Healthcare Systems Readiness: What is Limiting the RLT Scale-up? 28:25

2M ago28:25

28:25

Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it. Moderator: Ken Herrmann, MD (Universitä…

1
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02) 13:22

2M ago13:22

13:22

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’. Read the full article: https://ww…

1
The Silent Killer: The sci-fi episode, with Certa Therapeutics and University of Sydney CTC 27:59

2M ago27:59

27:59

Wearable kidneys. Organs on a chip. Xenotransplantation. The future is here. But is that the future people in biotech are truly looking to? Because the future that Certa Therapeutics CEO Darren Kelly is looking to is much less 1980s sci-fi and more... Apple watch. And in a future where the numbers point to a rise in lifestyle diseases thanks to die…

1
The Silent Killer: Prevention is the next cure, with Kidney Health Australia and Proteomics International 23:06

2M ago23:06

23:06

We may have led you on a bit in the first two episodes... kidney disease is still a big problem despite the massive shifts forward in treating it. There is a long way to go to bring medical sectors -- and governments -- along as well. This episode features Breonny Robson, general manager of clinical and research at Kidney Health Australia and Richa…

1
The Silent Killer: Who has the killer apps? With Dimerix and PYC Therapeutics 24:40

2M ago24:40

24:40

We speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease focal segmental glomerulosclerosis (FSGS). And we talk to PYC Therapeutics CEO Dr Rohan Hockings about how his company's tech actually works to treat polycystic kidney disease.…

1
The Silent Killer: Why biotechs are all in on kidney disease, with University of Sydney CTC and Chris Kallos 26:54

3M ago26:54

26:54

Kidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done. But in the last five years there's been a surge of work that's resulted in the FDA approving some blockbuster drugs in the last 18 months. Billion-dollar takeovers are now on the table and the tiny number of Australian biotechs in this s…

1
Emmy Boerrigter on dose selection of novel anticancer drugs 11:41

3M ago11:41

11:41

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lan…

1
Phase III Trailer 0:39

3M ago0:39

0:39

Life sciences more than anywhere else is the successful mashup of money and tech. I'm Rachel Williamson and this is Phase III, a weekly podcast diving deep into Australian life sciences. In each of our short series, we investigate, interrogate, and explore the most exciting companies and ideas in health science and the investment case for what they…

1
Advocacy in Action: Insights from a Visionary Shaping the Present Landscape of Nuclear Medicine 17:51

3M ago17:51

17:51

Join us on this episode as we welcome Cybil Nielsen, a leading figure in the nuclear medicine community. Cybil brings her extensive experience and advocacy efforts to the forefront, discussing her work with legislative initiatives impacting the field. Tune in to hear her insights on the future of nuclear medicine, the critical role of policy change…

1
The Standard of Care for Metastatic Prostate Cancer 34:00

3M ago34:00

34:00

The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in com…

1
Current Updates in Brain Imaging and Neurodegenerative Diseases

4M ago

—

Guest: Phillip H. Kuo, MD, PhD One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the brain, which is one of the culprit proteins in Alzheimer's disease. To learn more about this presentation fro…

1
Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals in mCRPC

4M ago

—

Guest: Geoffrey B. Johnson, M.D., Ph.D. When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things in their body, including the salivary glands. To learn more about his recent study on salivary toxicity, jo…

1
A Look at the Utility of PSMA PET Scans in Prostate Cancer

4M ago

—

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto th…

1
The Evolving AI Landscape in Nuclear Medicine

4M ago

—

Guest: Joyita Dutta The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what’s on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in …

1
Highlighting the Current Status and Future of Theranostics

4M ago

—

Guest: Geoffrey B. Johnson, M.D., Ph.D. Clinicians are hopeful that theranostics could help treat patients as soon as they go metastatic or even before surgery to try to affect their therapy and possibly get them to avoid having to take toxic or high side effect therapies. To hear more, tune in with Dr. Geoffrey Johnson, Nuclear Medicine Specialist…

1
AI in Nuclear Medicine: Improvements in the Field

4M ago

—

Guest: Chi Liu, PhD The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more about his presentation from SNMMI 2024.

1
Diving into New Directions of Radiopharmaceuticals

4M ago

—

Guest: Brianna Cagle The Discovery Team at Perspective has developed a compound, called PSV-359, which is a cyclic peptide radiopharmaceutical. It targets a protein, called fibroblast activation protein (FAP), which is a pan-cancer target and is expressed in a wide variety of cancers. To learn more about her presentation from SNMMI 2024, hear from …

1
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations 36:56

4M ago36:56

36:56

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints. Tell us what you thought about this episode Continue this conversation on social! F…

1
A Look at the Horizon of Cancer Vaccines

4M ago

—

Guest: Lillian Siu, MD, FRCPC With a few studies in the works for cancer vaccines, the future is exciting for what this could mean for oncology patients. Dive in to learn about the various ways to package cancer vaccines so they can be delivered to patients effectively. And to learn more about the limitations, targets, and platforms of cancer vacci…

1
A Unique Look at the Current and Future Directions of Cancer Vaccines

4M ago

—

Guest: Lillian Siu, MD, FRCPC Since cancer vaccines have been of interest to oncologists for decades, they’ve been trying to figure out how to prime or stimulate the immune system to attack cancer, and until the last few years, cancer vaccines have been challenging. To learn about this unique area of study, which she also presented at ASCO 2024, jo…

1
Decoding Risk: Genetic Testing in High-Risk Colon Cancer Patients

4M ago

—

Host: Jody Takemoto, PhD Guest: Bryson Katona, MD, PhD At the 2024 Digestive Disease Week Annual Meeting, Dr. Bryson Katona presented a session, titled “High-Risk Colon Cancer: The ABCs of Genetic Testing.” And now, Dr. Katona is here with Dr. Jody Takemoto to share key insights from his session on genetic testing for patients with high-risk colon …

1
Diving into the Details of Upadacitinib for UC and Crohn’s Disease

4M ago

—

Guest: Andres J. Yarur, MD Obesity has recently surfaced as an important topic in patients with inflammatory bowel diseases, such as Crohn’s and ulcerative colitis, but historically, these patients have been underweight. This led to the phase III pivotal trials for the use of upadacitinib in patients with moderate to severe ulcerative colitis and C…

1
Updates on New Technologies and Imaging Agents in Healthcare

5M ago

—

Guest: Tyler J Bradshaw, PhD In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more …

1
The Future of Medicine: An In-Depth Look at Theranostics and Clinical Trials 26:14

5M ago26:14

26:14

Welcome to another episode of the Nuclear Lounge Podcast! Today, we have a very special guest with us, someone whose contributions to the field of nuclear medicine are truly remarkable. Tina Brennan is a seasoned professional with over 22 years of experience in nuclear medicine. Her extensive career has seen her evolve from a passionate beginner to…

1
Advances in Dementia Imaging: Insights from Experts 29:07

5M ago29:07

29:07

The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine …

1
Alpha is More Than Just Ac-225: Pb-212 21:19

5M ago21:19

21:19

This month's episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges. Moderator Ken Herrmann, MD,…

1
The Future of FAPI Therapy 43:24

5M ago43:24

43:24

The Journal of Nuclear Medicine presents a new podcast on FAPI-directed theranostics for cancer diagnosis and treatment. Join moderator Ken Herrmann (Universitätsmedizin) and panelists Andrew Scott (Austin Health), Katharina Lückerath (Universitätsmedizin) and Shadi Esfahadi (Mass General Hospital) as they delve into the history of FAP, discuss cha…

1
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment 24:08

5M ago24:08

24:08

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it. Tell us what you thought about this episode Continue this conversatio…

1
Keys to Maneuvering Discrepancies in Clinical Practice Guidelines

6M ago

—

Guest: Jason Busse, PhD Different clinical practice guidelines often have discrepancies from one another, making it a challenge for clinicians to determine which ones are more trustworthy. Here to break down the things clinicians should look for when sorting between guidelines that give discrepant recommendations is Dr. Jason Busse, who presented a…

1
Considerations for Using Opioids and Cannabis to Treat Chronic Pain

6M ago

—

Guest: Jason Busse, PhD In light of the opioid epidemic, the use of cannabis for therapeutic purposes is becoming of interest. But since there are other alternatives that are often more effective and have better safety profiles, it’s important to understand the evidence and guideline recommendations around these two treatment options. Here to share…

1
Managing Osteoporosis: How to Create Personalized Treatment Plans

6M ago

—

Host: Michael Lewiecki, MD, FACP, FACE Although step therapy is the approach that many health plans and organizations are fond of, individualizing treatment decisions for patients with osteoporosis is essential, especially those who are at risk of fractures. To learn how you can create personalized treatment plans for patients with osteoporosis, tu…

1
Concepts in Osteoporosis Care: Coverage, Sequencing, and Comparative Effectiveness

6M ago

—

Host: Michael Lewiecki, MD, FACP, FACE Here to talk about current concepts in the management of osteoporosis like insurance coverage, therapy sequencing, and comparative effectiveness is Dr. Michael Lewiecki, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.

1
Positron Range Correction PET, Hunor Kertesz, Image X institute Video

6M ago

—

Positron Range Correction PET Hunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-ge…

1
Positron Range Correction PET Hunor Kertesz Image X institute Audio

6M ago

—

Positron Range Correction PET Hunor Kertesz Image X institute @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-ge…

1
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean 35:05

6M ago35:05

35:05

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagno…

1
Insights on the Rising Rates of Syphilis in the United States

6M ago

—

Guest: Ina Park, MD The United States has seen its largest increase in syphilis cases in the past five years. And with increases prevalent in every region, along with a shortage of medication, additional surveillance strategies and importation resources are necessary. Dive in for a discussion on the challenges and strategies to combat the spread of…

1
Empowering Excellence in Nuclear Medicine: Insights from a Pioneering Expert 26:19

6M ago26:19

26:19

Lisa Hazen is a distinguished professional with extensive experience in the dynamic field of nuclear medicine. Her career has spanned diverse roles, including training, sales, marketing, and management within the healthcare and pharmaceutical industries. Lisa's expertise and dedication have led to remarkable achievements, from increasing social med…

1
Exploring the Role of Nutrition in Managing Neurological Disorders

6M ago

—

Host: Karima Benameur, MD According to recent data, nutrition plans like the Mediterranean, DASH, and MIND diets can help patients with a variety of neurological diseases, including multiple sclerosis, stroke, and dementia. Tune in to hear Dr. Karima Benameur discuss this research and how we can counsel patients with neurological diseases about nut…

1
Understanding Pain Management in Children with Neurological Disorders

6M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Lauren Treat, MD Guest: Wendy Gaultney, MD Children who have neurological disorders and experience pain are often not able to articulate how their pain affects them. That’s why it’s important for clinicians to understand the brain’s role in the experience of pain and how to help these patients and the…

Podcasts que valem a pena ouvir

Podcasts sobre Theranostics

Podcasts que valem a pena ouvir

Guia rápido de referências